Compare GEVO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | ZNTL |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.7M | 165.1M |
| IPO Year | 2010 | 2020 |
| Metric | GEVO | ZNTL |
|---|---|---|
| Price | $1.81 | $1.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $5.11 | ★ $7.44 |
| AVG Volume (30 Days) | ★ 4.4M | 1.4M |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $711,000.00 | N/A |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $1.28 |
| 52 Week High | $2.97 | $6.95 |
| Indicator | GEVO | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 72.13 | 33.46 |
| Support Level | $1.62 | $1.63 |
| Resistance Level | $1.91 | $2.76 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 71.49 | 19.47 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.